Exercise in preventing falls for men with prostate cancer: a modelled cost-utility analysis

被引:3
|
作者
Edmunds, Kim [1 ]
Scuffham, Paul [2 ]
Newton, Robert U. [3 ]
Galvao, Daniel A. [3 ]
Tuffaha, Haitham [1 ]
机构
[1] Univ Queensland, Ctr Business & Econ Hlth, Brisbane, Qld 4072, Australia
[2] Griffith Univ, Menzies Hlth Inst Queensland, Gold Coast, Australia
[3] Edith Cowan Univ, Exercise Med Res Inst, Joondalup, Australia
关键词
Economic evaluation; Cost-utility analysis; Exercise medicine; Physical activity; Prostate cancer; Androgen deprivation therapy; QUALITY-OF-LIFE; OLDER-PEOPLE; ANDROGEN DEPRIVATION; ECONOMIC-EVALUATION; CONTROLLED-TRIAL; HEALTH; PROGRAM; GUIDELINES; RADIATION; SURVIVORS;
D O I
10.1007/s00520-022-06900-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction Men who receive androgen deprivation therapy (ADT) for prostate cancer (PCa) are a vulnerable falls population due to the side effects of treatment. The purpose of this paper is to determine the cost-effectiveness of exercise in preventing falls and fractures for this high-risk population in Australia. Methods A decision analytic model was constructed to evaluate the cost utility of an exercise intervention compared to usual care from a health system perspective. The intervention comprised two 1-h sessions of supervised exercise per week over 1 year for men with non-metastatic PCa receiving curative radiation therapy and ADT. A Markov model simulated the transition between five health states: (1) at risk of falling; (2) at recurrent risk of falling; (3) fracture (minor or major); (4) non-fracture injury (minor or major); and (5) death. Model inputs including transition probabilities and utility scores were obtained from published meta-analyses, and costs were drawn from Australian data sources (e.g. Medical Benefits Schedule). The model time horizon was 3 years, and costs and effects were discounted at 5% annual rate. Costs and quality-adjusted life years (QALYs) were aggregated and compared between the intervention and control to calculate incremental net monetary benefit (iNMB). Uncertainty in the results was explored using deterministic and probabilistic sensitivity analyses (PSA). Results At a willingness-to-pay of AU$50,000 per QALY, the exercise intervention dominated, as it was less costly and more effective than usual care. The iNMB was $3010 per patient. The PSA showed a 58% probability the intervention was cost-effective. Conclusion This is the first modelled economic evaluation of exercise for men with PCa. Our results suggest supervised exercise is cost-effective in reducing the risks of falls and fractures in this population.
引用
收藏
页码:5037 / 5046
页数:10
相关论文
共 50 条
  • [1] Exercise in preventing falls for men with prostate cancer: a modelled cost-utility analysis
    Kim Edmunds
    Paul Scuffham
    Robert U. Newton
    Daniel A. Galvão
    Haitham Tuffaha
    Supportive Care in Cancer, 2022, 30 : 5037 - 5046
  • [2] Exercise in preventing falls and fractures for men with prostate cancer receiving androgen deprivation therapy: A modelled cost-utility analysis
    Edmunds, Kim
    Scuffham, Paul
    Newton, Rob U.
    Galvao, Daniel A.
    Tuffaha, Haitham
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 93 - 93
  • [3] COST-UTILITY ANALYSIS OF EXERCISE FOR THE PREVENTION OF CANCER
    O'Day, K.
    Campbell, D. J.
    VALUE IN HEALTH, 2016, 19 (07) : A740 - A740
  • [4] Interpreting cost-utility analysis of prostate cancer treatment
    James B. Yu
    Nature Reviews Urology, 2013, 10 : 129 - 131
  • [5] A Cost-Utility Analysis of Prostate Cancer Screening in Australia
    Keller, Andrew
    Gericke, Christian
    Whitty, Jennifer A.
    Yaxley, John
    Kua, Boon
    Coughlin, Geoff
    Gianduzzo, Troy
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2017, 15 (01) : 95 - 111
  • [6] Interpreting cost-utility analysis of prostate cancer treatment
    Yu, James B.
    NATURE REVIEWS UROLOGY, 2013, 10 (03) : 129 - 131
  • [7] A Cost-Utility Analysis of Prostate Cancer Screening in Australia
    Andrew Keller
    Christian Gericke
    Jennifer A. Whitty
    John Yaxley
    Boon Kua
    Geoff Coughlin
    Troy Gianduzzo
    Applied Health Economics and Health Policy, 2017, 15 : 95 - 111
  • [8] A COST-UTILITY ANALYSIS OF DEGARELIX IN THE TREATMENT OF PROSTATE CANCER IN CHINA
    Yang, F.
    Du, X.
    Xuan, J.
    Fei, J.
    VALUE IN HEALTH, 2019, 22 : S35 - S36
  • [9] COST-UTILITY ANALYSIS OF CANCER CARE
    OESER, H
    KOEPPE, P
    MUNCHENER MEDIZINISCHE WOCHENSCHRIFT, 1984, 126 (09): : A38 - &
  • [10] A cost-utility analysis of apalutamide for metastatic castration-sensitive prostate cancer
    Parmar, Ambica
    Timilshina, Narhari
    Emmenegger, Urban
    Smoragiewicz, Martin
    Sander, Beate
    Alibhai, Shabbir
    Chan, Kelvin K. W.
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2022, 16 (03): : E126 - E131